Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline includes THR-149, a plasma kallikrein inhibitor currently in Phase II development for diabetic macular edema (DME), and THR-687, an integrin antagonist also undergoing Phase II trials for DME.